These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]
6. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"]. Tamaoka A Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Alzheimer's disease. Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646 [TBL] [Abstract][Full Text] [Related]
8. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease]. Abe K Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy against amyloid pathology in Alzheimer's disease. Galimberti D; Ghezzi L; Scarpini E J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047 [TBL] [Abstract][Full Text] [Related]
11. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps]. Kuzuhara S Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870 [TBL] [Abstract][Full Text] [Related]
12. [Development of Disease-modifying Therapy for Alzheimer's Disease]. Akiyama H Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864 [TBL] [Abstract][Full Text] [Related]
13. [Expression of apolipoprotein E in Alzheimer's disease and its significance]. He SR; Liu DG; Wang S; Xia YJ Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304 [TBL] [Abstract][Full Text] [Related]
14. Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation. Luan K; Rosales JL; Lee KY Ageing Res Rev; 2013 Jan; 12(1):174-81. PubMed ID: 22728532 [TBL] [Abstract][Full Text] [Related]
15. Disease modifying therapy for AD? Golde TE J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654 [TBL] [Abstract][Full Text] [Related]
16. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD. Thal DR; Fändrich M Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324 [No Abstract] [Full Text] [Related]
17. Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. Nunomura A; Castellani RJ; Lee HG; Moreira PI; Zhu X; Perry G; Smith MA Sci Aging Knowledge Environ; 2006 May; 2006(8):pe10. PubMed ID: 16672726 [TBL] [Abstract][Full Text] [Related]
18. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. Bloom GS JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463 [TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis of Alzheimer's disease: molecular and cellular mechanisms]. Govaerts L; Schoenen J; Bouhy D Rev Med Liege; 2007 Apr; 62(4):209-16. PubMed ID: 17566391 [TBL] [Abstract][Full Text] [Related]
20. A critical analysis of the 'amyloid cascade hypothesis'. Armstrong RA Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]